Aurobindo Pharma Limited announced its consolidated financial results for the quarter ended September 30, 2023. Revenue from Operations increased by 25.8% YoY to Rs. 7,219 crore with growth seen across key segments. The company reported net profit after share of profit/loss of JV and minority interest at Rs. 752 crore, vs. Rs. 409 crore in Q2FY23.

Commenting on the Company’s performance, K. Nithyananda Reddy, Vice-Chairman and Managing Director of the Company said: “This is yet another quarter with highest ever sales, driven by robust performance across the markets, and continued margin expansion, aided by operational leverage and efficiencies. With our strong product pipeline, focus on compliance and key projects in advanced stages, we will continue our growth journey, while generating value for our stakeholders.”